IDEXX EVP Michael Lane sells 3,979 shares

A footnote identifies 31 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, June 30 and September 30, 2026.

Available on EDGAR 11/05/2026 - 05:02 PM EST Accepted by SEC EDGAR 11/05/2026 - 05:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President Michael Lane reported three direct sales of common stock on November 4, 2026, totaling 3,979 shares. The reported prices were $687.85 for 243 shares, $689.70 for 2,059 shares, and a weighted average of $687.4586 per share for 1,677 shares; that last sale covered a price range of $687.0701 to $687.50. No Rule 10b5-1 plan is reported. A separate holding entry lists 592 shares held by his spouse in an IRA; Lane disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Net Seller: 3,978.944 shares

Net Sell 3 txns

Insider Lane Michael

Role Executive Vice President

Sold 3,978.944 shs ($2.74M)

Share of Position Sold 49.4%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	242.944	$687.85	$167K
Sale	Common Stock	2,059	$689.70	$1.42M
Sale	Common Stock F2	1,677	$687.4586	$1.15M
Holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 4,076 shares (Direct); Common Stock — 592 shares (Indirect, by spouse)

Holdings Before and After: Common Stock, 8,054.944 to 4,076 shares (Direct)

Other Insiders: 3 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. Includes a total of 31 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026, June 30, 2026 and September 30, 2026.
2. F2. Represents the weighted average price of the shares sold ranging from a low of $687.0701 to a high of $687.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
3. F3. Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

Key Figures

Total shares sold: 3,979 shares Shares sold: 243 shares Sale price: $687.85 per share +5 more

8 metrics

Total shares sold 3,979 shares Three direct sales reported on November 4, 2026

Shares sold 243 shares Direct sale on November 4, 2026; rounded from 242.944 shares

Sale price $687.85 per share Direct sale on November 4, 2026

Shares sold 2,059 shares Direct sale on November 4, 2026

Sale price $689.70 per share Direct sale on November 4, 2026

Shares sold 1,677 shares Direct sale on November 4, 2026

Weighted-average sale price $687.4586 per share The reported price range was $687.0701 to $687.50 per share

Shares held by spouse 592 shares Holding entry dated November 4, 2026; held in the spouse's IRA

Key Terms

weighted average price, Issuer Employee Stock Purchase Plan, IRA account, pecuniary interest, +1 more

5 terms

weighted average price financial

"Represents the weighted average price of the shares sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Issuer Employee Stock Purchase Plan financial

"purchased under the Issuer Employee Stock Purchase Plan"

IRA account financial

"Held by the reporting person's spouse in an IRA account"

pecuniary interest financial

"except to the extent of his pecuniary interest therein"

beneficial ownership regulatory

"disclaims beneficial ownership of the shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did IDXX executive Michael Lane sell, and when?

Michael Lane reported sales totaling 3,979 shares of IDEXX Laboratories common stock on November 4, 2026. The three reported sale entries were 243, 2,059 and 1,677 shares.

What prices did Michael Lane report for his IDXX share sales?

The reported prices were $687.85 per share for 243 shares and $689.70 per share for 2,059 shares. For 1,677 shares, the reported weighted-average price was $687.4586 per share, with a stated range of $687.0701 to $687.50.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lane Michael

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK MAINE 04092

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2026		S		242.944	D	$687.85	7,812(1)	D
Common Stock	11/04/2026		S		2,059	D	$689.7	5,753	D
Common Stock	11/04/2026		S		1,677	D	$687.4586(2)	4,076	D
Common Stock								592(3)	I	by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes a total of 31 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2026, June 30, 2026 and September 30, 2026.

2. Represents the weighted average price of the shares sold ranging from a low of $687.0701 to a high of $687.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

3. Held by the reporting person's spouse in an IRA account. The reporting person disclaims beneficial ownership of the shares of common stock held by his spouse except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Michael Lane	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)